摘要
目的 改善肿瘤细胞共刺激分子B7的表达。方法 将ALA970 2 肺癌细胞与活化的B淋巴细胞用聚乙二醇进行细胞融合 ,经ELISA及免疫细胞化学筛选后 ,用S P免疫细胞化学染色观察融合细胞的肺癌抗原及B7分子的表达 ,并观察融合细胞的体内外生长情况。结果 经筛选获得一株融合细胞FLB2C。融合细胞既表达肺癌抗原 ,又表达B7分子。体外培养显示其贴壁性较ALA970 2 肺癌细胞减弱 ,生长明显变缓 ,细胞倍增时间延长 ,不能在软琼脂中形成集落。接种融合细胞亦不能在小鼠体内成瘤 ,而接种ALA970 2 细胞的 10只小鼠中 6例腋下出现肿瘤生长 ,3例还发生肺转移。结论 通过细胞融合方法可以有效改善肿瘤细胞的B7分子表达 ,从而提高肿瘤细胞的抗原性。融合细胞FLB2C的致瘤性明显减弱 ,为制备更有效的肺癌疫苗奠定了基础。
Objective To ameliorate expression B 7 molecule of tumor cell. Methods Mouse lung cancer cell line ALA 9702 and active B lymphocytes were fused by polyethylene glycol. After screening with ELISA and immunocytochemistry, the expression of lung cancer antigen and B 7 molecule in the fusion cells were monitored by S P immunocytochemistry staining. Proliferation of the fusion cells was observed in vitro and in vivo. Results A fusion cell line, FLB 2C , was obtained through screening. FLB 2C could express the lung cancer antigen and B 7 molecule. The results of in vitro culture showed that the wall adherence characteristic of FLB 2C was abated and the growth of FLB 2C was slower than that of ALA 9702 . The cell multiplication time of FLB 2C prolonged and no colony was formed in soft agar. No tumor mass was observed in vivo after inoculation of FLB 2C into mice. Conclusion Expression of B 7 molecule in tumor cell can be ameliorated through cell fusion, thereby antigenicity of tumor cell will be raised. The oncogenicity of FLB 2C is obviously weakened through fusion with normal cells. This provides the basis for preparation of better lung cancer vaccines.
出处
《中国肺癌杂志》
CAS
2000年第6期438-440,共3页
Chinese Journal of Lung Cancer
基金
国家自然科学基金(39800147)
卫生部基金(961236)资助
关键词
肺癌融合细胞
B_(7)分子表达
构建
生物学性质
Lung cancer fusion cell
Expression of B_(7)molecule
Establishment Biological feature
